| 產品名稱 |
455 |
| 商品貨號 |
B163751 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The antibody reacts with EGF receptors, but does not block the binding of EGF to the receptor on A-431 cells. 579, 225 or 528, see ATCC HB-8506, ATCC HB-8508 and ATCC HB-8509) to A-431 cells and binds with lower affinity than 528, 225 and 579. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Animals were immunized with partially purified EGF receptors from A-431 cells. Spleen cells were fused with NS-1-503 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against epidermal growth factor (EGF) receptor |
| Cellular Products |
immunoglobulin; monoclonal antibody; against epidermal growth factor (EGF) receptor |
| Tumorigenic |
Yes |
| Effects |
Yes, in pristane primed BALB/cJ mice |
| Comments |
Animals were immunized with partially purified EGF receptors from A-431 cells. Spleen cells were fused with NS-1-503 myeloma cells. The antibody reacts with EGF receptors, but does not block the binding of EGF to the receptor on A-431 cells. It does not inhibit the binding of other antibodies (e.g., 579, 225 or 528, see ATCC HB-8506, ATCC HB-8508 and ATCC HB-8509) to A-431 cells and binds with lower affinity than 528, 225 and 579. It only marginally inhibits the growth of A-431 tumor cells in vitro, and does not block EGF stimulated phosphorylation of membrane proteins. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: horse serum to a final concentration of 10%.
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Isotype |
IgG1 |
| Name of Depositor |
Regents of the University of California |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Mendelsohn J, et al. Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor. US Patent 4,943,533 dated Jul 24 1990
Sato JD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1: 511-529, 1983. PubMed: 6094961
|
